Updating the evidence on drugs to treat overactive bladder: a systematic review

Frances C. Hsu, Chandler E. Weeks, Shelley Selph, Ian Blazina, Rebecca S. Holmes, Marian McDonagh

Research output: Contribution to journalReview article

Abstract

Introduction: Overactive bladder (OAB) is a common condition, increasing with age and affecting quality of life. While numerous OAB drugs are available, persistence is low. We evaluated evidence published since 2012 to determine if newer drugs provided better efficacy and harm profiles. Methods: We searched MEDLINE and the Cochrane Library from 2012 to September 2018 using terms for included drugs and requested information from manufacturers of included drugs. We performed dual review of all systematic review processes, evaluated study quality, and conducted meta-analyses using random effects models. Results: In addition to 31 older studies, we included 20 trials published since 2012 (N = 16,478; 4 good, 11 fair, and 5 poor quality). Where statistical differences were found, they were clinically small (reductions of < 0.5 episodes/day). Solifenacin plus mirabegron improved efficacy outcomes over monotherapy with either drug, but significantly increased constipation compared with solifenacin and dry mouth compared with mirabegron. Solifenacin reduced incontinence over mirabegron and tolterodine and urgency episodes over tolterodine. Mirabegron did not differ from tolterodine in efficacy but had significantly lower incidence of dry mouth than solifenacin or tolterodine. Fesoterodine showed significant improvements but also anticholinergic effects vs. tolterodine. Oxybutynin, solifenacin, and tolterodine had similar efficacy, but dry mouth led to greater discontinuation with oxybutynin. Blurred vision, cardiac arrhythmia, and dizziness were uncommon. Conclusion: New evidence confirms small, but clinically uncertain, differences among monotherapies and also between combination and monotherapy, regardless of statistical significance. While drugs mainly differed in incidence of dry mouth or constipation, none provided improved efficacy without increased harms.

Original languageEnglish (US)
JournalInternational Urogynecology Journal
DOIs
StatePublished - Jan 1 2019

Fingerprint

Overactive Urinary Bladder
Mouth
Pharmaceutical Preparations
Constipation
Incidence
Cholinergic Antagonists
Dizziness
MEDLINE
Libraries
Meta-Analysis
Tolterodine Tartrate
Cardiac Arrhythmias
Quality of Life
Solifenacin Succinate
mirabegron

Keywords

  • Antimuscarinics
  • Meta-analysis
  • Mirabegron
  • Overactive bladder
  • Systematic review
  • Urgency urinary incontinence

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Urology

Cite this

Updating the evidence on drugs to treat overactive bladder : a systematic review. / Hsu, Frances C.; Weeks, Chandler E.; Selph, Shelley; Blazina, Ian; Holmes, Rebecca S.; McDonagh, Marian.

In: International Urogynecology Journal, 01.01.2019.

Research output: Contribution to journalReview article

@article{d52e254dd2214e679e7f1b12316356a6,
title = "Updating the evidence on drugs to treat overactive bladder: a systematic review",
abstract = "Introduction: Overactive bladder (OAB) is a common condition, increasing with age and affecting quality of life. While numerous OAB drugs are available, persistence is low. We evaluated evidence published since 2012 to determine if newer drugs provided better efficacy and harm profiles. Methods: We searched MEDLINE and the Cochrane Library from 2012 to September 2018 using terms for included drugs and requested information from manufacturers of included drugs. We performed dual review of all systematic review processes, evaluated study quality, and conducted meta-analyses using random effects models. Results: In addition to 31 older studies, we included 20 trials published since 2012 (N = 16,478; 4 good, 11 fair, and 5 poor quality). Where statistical differences were found, they were clinically small (reductions of < 0.5 episodes/day). Solifenacin plus mirabegron improved efficacy outcomes over monotherapy with either drug, but significantly increased constipation compared with solifenacin and dry mouth compared with mirabegron. Solifenacin reduced incontinence over mirabegron and tolterodine and urgency episodes over tolterodine. Mirabegron did not differ from tolterodine in efficacy but had significantly lower incidence of dry mouth than solifenacin or tolterodine. Fesoterodine showed significant improvements but also anticholinergic effects vs. tolterodine. Oxybutynin, solifenacin, and tolterodine had similar efficacy, but dry mouth led to greater discontinuation with oxybutynin. Blurred vision, cardiac arrhythmia, and dizziness were uncommon. Conclusion: New evidence confirms small, but clinically uncertain, differences among monotherapies and also between combination and monotherapy, regardless of statistical significance. While drugs mainly differed in incidence of dry mouth or constipation, none provided improved efficacy without increased harms.",
keywords = "Antimuscarinics, Meta-analysis, Mirabegron, Overactive bladder, Systematic review, Urgency urinary incontinence",
author = "Hsu, {Frances C.} and Weeks, {Chandler E.} and Shelley Selph and Ian Blazina and Holmes, {Rebecca S.} and Marian McDonagh",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s00192-019-04022-8",
language = "English (US)",
journal = "International Urogynecology Journal and Pelvic Floor Dysfunction",
issn = "0937-3462",
publisher = "Springer London",

}

TY - JOUR

T1 - Updating the evidence on drugs to treat overactive bladder

T2 - a systematic review

AU - Hsu, Frances C.

AU - Weeks, Chandler E.

AU - Selph, Shelley

AU - Blazina, Ian

AU - Holmes, Rebecca S.

AU - McDonagh, Marian

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction: Overactive bladder (OAB) is a common condition, increasing with age and affecting quality of life. While numerous OAB drugs are available, persistence is low. We evaluated evidence published since 2012 to determine if newer drugs provided better efficacy and harm profiles. Methods: We searched MEDLINE and the Cochrane Library from 2012 to September 2018 using terms for included drugs and requested information from manufacturers of included drugs. We performed dual review of all systematic review processes, evaluated study quality, and conducted meta-analyses using random effects models. Results: In addition to 31 older studies, we included 20 trials published since 2012 (N = 16,478; 4 good, 11 fair, and 5 poor quality). Where statistical differences were found, they were clinically small (reductions of < 0.5 episodes/day). Solifenacin plus mirabegron improved efficacy outcomes over monotherapy with either drug, but significantly increased constipation compared with solifenacin and dry mouth compared with mirabegron. Solifenacin reduced incontinence over mirabegron and tolterodine and urgency episodes over tolterodine. Mirabegron did not differ from tolterodine in efficacy but had significantly lower incidence of dry mouth than solifenacin or tolterodine. Fesoterodine showed significant improvements but also anticholinergic effects vs. tolterodine. Oxybutynin, solifenacin, and tolterodine had similar efficacy, but dry mouth led to greater discontinuation with oxybutynin. Blurred vision, cardiac arrhythmia, and dizziness were uncommon. Conclusion: New evidence confirms small, but clinically uncertain, differences among monotherapies and also between combination and monotherapy, regardless of statistical significance. While drugs mainly differed in incidence of dry mouth or constipation, none provided improved efficacy without increased harms.

AB - Introduction: Overactive bladder (OAB) is a common condition, increasing with age and affecting quality of life. While numerous OAB drugs are available, persistence is low. We evaluated evidence published since 2012 to determine if newer drugs provided better efficacy and harm profiles. Methods: We searched MEDLINE and the Cochrane Library from 2012 to September 2018 using terms for included drugs and requested information from manufacturers of included drugs. We performed dual review of all systematic review processes, evaluated study quality, and conducted meta-analyses using random effects models. Results: In addition to 31 older studies, we included 20 trials published since 2012 (N = 16,478; 4 good, 11 fair, and 5 poor quality). Where statistical differences were found, they were clinically small (reductions of < 0.5 episodes/day). Solifenacin plus mirabegron improved efficacy outcomes over monotherapy with either drug, but significantly increased constipation compared with solifenacin and dry mouth compared with mirabegron. Solifenacin reduced incontinence over mirabegron and tolterodine and urgency episodes over tolterodine. Mirabegron did not differ from tolterodine in efficacy but had significantly lower incidence of dry mouth than solifenacin or tolterodine. Fesoterodine showed significant improvements but also anticholinergic effects vs. tolterodine. Oxybutynin, solifenacin, and tolterodine had similar efficacy, but dry mouth led to greater discontinuation with oxybutynin. Blurred vision, cardiac arrhythmia, and dizziness were uncommon. Conclusion: New evidence confirms small, but clinically uncertain, differences among monotherapies and also between combination and monotherapy, regardless of statistical significance. While drugs mainly differed in incidence of dry mouth or constipation, none provided improved efficacy without increased harms.

KW - Antimuscarinics

KW - Meta-analysis

KW - Mirabegron

KW - Overactive bladder

KW - Systematic review

KW - Urgency urinary incontinence

UR - http://www.scopus.com/inward/record.url?scp=85069728992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069728992&partnerID=8YFLogxK

U2 - 10.1007/s00192-019-04022-8

DO - 10.1007/s00192-019-04022-8

M3 - Review article

AN - SCOPUS:85069728992

JO - International Urogynecology Journal and Pelvic Floor Dysfunction

JF - International Urogynecology Journal and Pelvic Floor Dysfunction

SN - 0937-3462

ER -